The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease
Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory disease, is manifested with recurrent and chronic inflammation and amyloid A (AA) amyloidosis, driven by overproduction of interleukin 1 (IL-1) through an activated pyrin inflammasome. Consequently, non-responsiveness t...
Main Authors: | Eitan Giat, Ilan Ben-Zvi, Merav Lidar, Avi Livneh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/7/3956 |
Similar Items
-
Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
by: Ali Şahin, et al.
Published: (2020-01-01) -
Anakinra induces complete remission of nephrotic syndrome in a patient with familial Mediterranean fever and amyloidosis
by: Ángel M. Sevillano, et al.
Published: (2016-01-01) -
Screening for Fabry’s disease in a high-risk subpopulation of FMF
by: Tomer Maller, et al.
Published: (2022-10-01) -
Egyptian evidence-based consensus on clinical practice recommendations for the management of familial Mediterranean fever
by: S. Salah, et al.
Published: (2022-06-01) -
Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review
by: Rosa Talerico, et al.
Published: (2020-05-01)